Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

NCT01924793 is registered in ClinicalTrials.gov with Ansun Biopharma, Inc. as lead sponsor.

NCT NCT01924793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01924793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
Lead sponsor
Ansun Biopharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2013
Completion date
May 31, 2017
Enrollment
23 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

parainfluenza